Pfizer is one of the world’s leading pharmaceutical companies.
Pfizer reported full year 2025 revenues of $62.6 billion — a modest decline from 2024 — as post-COVID revenue normalization continued. Excluding Paxlovid and Comirnaty, Pfizer’s non-COVID portfolio grew at approximately 6% operationally in 2025. Pfizer’s $43 billion acquisition of Seagen in 2023 must now deliver the ADC-led oncology growth platform that CEO Albert Bourla described as the most important acquisition in Pfizer’s history. Seagen’s ADC technology including Padcev and Adcetris and the pipeline of next-generation ADC programs represent Pfizer’s primary pathway to re-establishing growth at scale.
This report provides comprehensive strategic intelligence on Pfizer — covering strategic directions, financial performance, SWOT analysis, technological know-how, latest products and services, M&A, marketing tactics, and organization and management.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Financial performance 2023-2025
• SWOT analysis
• Technological know-how and key platforms
• Latest products, programs, and innovation pipeline
• M&A activity 2023-2025
• Marketing tactics and commercial strategy
• Organization and management
Table of Contents
1. Executive Summary
2. Strategic Directions
3. Financial Performance
4. SWOT Analysis
5. Technological Know-How
6. Latest Products and Services
7. M&A
8. Marketing Tactics
9. Organization and Management
10. Appendix
List of Tables
Table 1. Pfizer — Key Financial Metrics 2023-2025
Table 2. Pfizer — Revenue by Therapeutic Area 2023-2025
Table 3. Pfizer — Revenue by Geography 2023-2025
Table 4. Pfizer — R&D Investment 2023-2025
Table 5. Pfizer — SWOT Analysis
Table 6. Pfizer — Key Technology Platforms
Table 7. Pfizer — Top Products by Revenue 2025
Table 8. Pfizer — Late-Stage Pipeline 2025
Table 9. Pfizer — M&A Activity 2023-2025
Table 10. Pfizer — Key Management
Table 11. Pfizer — Strategic Priorities 2025-2030
